Nuveen Asset Management, LLC Chemo Centryx, Inc. Transaction History

Nuveen Asset Management, LLC

$345 Billion
Q3 2024

Shares

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2022 Nov 14, 2022	SELL	$22.17 - $51.8 $1.03 Million - $2.42 Million	-46,655 Reduced 5.23%	845,023 $43.7 Million
Q2 2022 Aug 15, 2022	BUY	$15.36 - $27.51 $5.11 Million - $9.16 Million	332,802 Added 59.55%	891,678 $22.1 Million
Q1 2022 May 16, 2022	BUY	$22.22 - $39.12 $3.85 Million - $6.79 Million	173,453 Added 45.0%	558,876 $13.6 Million
Q4 2021 Feb 14, 2022	BUY	$18.38 - $40.5 $3.28 Million - $7.22 Million	178,325 Added 86.11%	385,423 $14 Million
Q3 2021 Nov 12, 2021	SELL	$13.18 - $19.83 $159,860 - $240,518	-12,129 Reduced 5.53%	207,098 $3.54 Million
Q2 2021 Aug 16, 2021	SELL	$9.59 - $50.88 $2.43 Million - $12.9 Million	-253,488 Reduced 53.62%	219,227 $2.94 Million
Q1 2021 May 17, 2021	BUY	$49.53 - $68.4 $12.6 Million - $17.4 Million	254,402 Added 116.53%	472,715 $24.2 Million
Q4 2020 Feb 16, 2021	SELL	$47.25 - $65.16 $13.2 Million - $18.2 Million	-279,496 Reduced 56.15%	218,313 $1.76 Million
Q3 2020 Nov 16, 2020	BUY	$46.35 - $61.69 $2.94 Million - $3.91 Million	63,428 Added 14.6%	497,809 $4.01 Million
Q2 2020 Aug 14, 2020	SELL	$38.58 - $65.07 $578,931 - $976,440	-15,006 Reduced 3.34%	434,381 $3.5 Million
Q1 2020 May 14, 2020	BUY	$32.73 - $50.78 $1.92 Million - $2.97 Million	58,534 Added 14.98%	449,387 $18.1 Million
Q4 2019 Feb 14, 2020	BUY	$6.81 - $39.55 $952,671 - $5.53 Million	139,893 Added 55.74%	390,853 $15.5 Million
Q3 2019 Nov 14, 2019	SELL	$6.47 - $8.96 $985,503 - $1.36 Million	-152,319 Reduced 37.77%	250,960 $1.7 Million
Q2 2019 Aug 15, 2019	BUY	$8.31 - $14.85 $3.35 Million - $5.99 Million	403,279 New	403,279 $3.75 Million

Others Institutions Holding CCXI

# of Institutions

6

Shares Held

66.3K

Call Options Held

0

Put Options Held

0

About ChemoCentryx, Inc.

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

More about CCXI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nuveen Asset Management, LLC with notifications on news.